Sonova Holding (OTCMKTS:SONVY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Sonova Holding (OTCMKTS:SONVY) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company.

Several research firms have commented on SONVY. BNP Paribas Exane upgraded Sonova from a “strong sell” rating to a “strong-buy” rating in a research report on Tuesday, March 10th. Zacks Research upgraded shares of Sonova from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Finally, Jefferies Financial Group lowered shares of Sonova from a “hold” rating to a “moderate sell” rating in a report on Wednesday, March 18th.

Sonova Trading Up 0.9%

Shares of SONVY stock opened at $43.29 on Friday. Sonova has a fifty-two week low of $42.26 and a fifty-two week high of $68.76. The stock’s fifty day moving average price is $51.58 and its two-hundred day moving average price is $52.98. The company has a quick ratio of 0.91, a current ratio of 1.24 and a debt-to-equity ratio of 0.51.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.